Zacks Investment Research·5 days ago
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ANI Pharmaceuticals, Inc.(ANIP)Earnings, Financials & Key Ratios
ANIP•NASDAQ
$85.05
25.6× P/E·Price updated Jul 6, 2026
AboutANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.Show more
- Revenue$883M+43.8%
- EBITDA$173M+152.7%
- Net Income$78M+522.9%
- EPS (Diluted)3.32+419.2%
- Gross Margin51.01%-13.9%
- EBITDA Margin19.54%+75.8%
- Operating Margin9.2%+9569.3%
- Net Margin8.87%+394.1%
- ROE16.16%+486.7%
ANIP Price & Volume
ANI Pharmaceuticals, Inc. (ANIP) stock price & volume — 10-year historical chart
Loading chart...
Specialty Pharma Pivot Drives Significant Margin Expansion
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Improving
Primary Risk:Payer reimbursement and pricing
Key Thesis Takeaways
- ANI Pharmaceuticals is successfully transitioning from a legacy generic manufacturer to a high-margin specialty player, evidenced by a 20.5% year-over-year revenue growth in 2026Q1.
- While the commercialization of Cortrophin Gel serves as a primary catalyst for profitability, investors should monitor the sustainability of these margins given the inherent volatility in payer reimbursement and the $9.8M quarterly stock-based compensation expense.
- The company's disciplined deleveraging strategy, which reduced the debt-to-equity ratio from 1.46 in 2024Q4 to 0.58 in 2026Q1, provides a more stable foundation for future operational scaling.
Verdict Logic
while the company has achieved a positive net income of $29.5M in 2026Q1, the forward P/E of 8.98 suggests market skepticism regarding the long-term sustainability of its specialty drug pricing power.
ANIP Growth Metrics
ANI Pharmaceuticals, Inc. (ANIP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years27.75%
5 Years33.48%
3 Years40.81%
TTM37.03%
Profit CAGR
10 Years17.68%
5 Years-
3 Years-
TTM526%
EPS CAGR
10 Years9.66%
5 Years-
3 Years-
TTM410.24%
Return on Capital
10 Years2.88%
5 Years0.24%
3 Years4.63%
Last Year7.21%
ANIP Recent Earnings
ANI Pharmaceuticals, Inc. (ANIP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$2.05+60.2%
$1.28
Rev
$237M+14.4%
$208M
Q1 2026
Feb 27, 2026Metric
Actual
Est
EPS
$2.33+17.1%
$1.99
Rev
$247M+6.9%
$231M
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$2.04+17.2%
$1.74
Rev
$228M-1.9%
$232M
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$1.80+30.4%
$1.38
Rev
$211M+1.2%
$209M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $2.05vs $1.28+60.2% | $237Mvs $208M+14.4% |
| Q1 2026 | Feb 27, 2026 | $2.33vs $1.99+17.1% | $247Mvs $231M+6.9% |
| Q4 2025 | Nov 7, 2025 | $2.04vs $1.74+17.2% | $228Mvs $232M-1.9% |
| Q3 2025 | Aug 8, 2025 | $1.80vs $1.38+30.4% | $211Mvs $209M+1.2% |
Based on last 12 quarters of dataView full earnings history →
Latest ANIP News
Recent stock market news and headlines for ANI Pharmaceuticals, Inc. (ANIP)
Seeking Alpha·Jun 26, 2026
ANI Pharmaceuticals: Rare Disease Growth At A Generics MultipleANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation. Management guides to $540M-$575M Cortrophin revenue in 2026, making rare disease close to 60% of total revenue and supporting a re-rating. A $108 fair value is based on 9x 2026 adjusted EBITDA, offering ~30% upside if Cortrophin growth and gout expansion materialize as guided.
Zacks Investment Research·Jun 16, 2026
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Peers Comparison
Key metrics vs top competitors for ANI Pharmaceuticals, Inc. (ANIP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $85.05 | $1.93B | 25.62 | 43.78% | 8.87% | 16.16% | 0.06% | |
| $16.92 | $5.4B | 76.91 | 8.05% | 4.02% | — | — | |
| $102.82 | $6.69B | 30.15 | 0.5% | 18.05% | 24.33% | — | |
| $11.09 | $1.53B | -1.08 | -2.75% | -43.5% | -50.65% | — | |
| $34.13 | $1.38B | 28.68 | 27.37% | 6.35% | 29.49% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — |
Compare ANIP vs Peers
ANI Pharmaceuticals, Inc. (ANIP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANIP SEC Filings & Documents
ANI Pharmaceuticals, Inc. (ANIP) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 8, 2026·SEC
Material company update
Apr 7, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when ANIP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANIP Frequently Asked Questions
ANI Pharmaceuticals, Inc. (ANIP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is ANI Pharmaceuticals, Inc.'s revenue?
ANI Pharmaceuticals, Inc. (ANIP) reported $923.7M in revenue for fiscal year 2025. This represents a 750508% increase from $0.1M in 1998.
How fast is ANI Pharmaceuticals, Inc. growing?
ANI Pharmaceuticals, Inc. (ANIP) grew revenue by 43.8% over the past year. This is strong growth.
Is ANIP profitable?
Yes, ANI Pharmaceuticals, Inc. (ANIP) is profitable, generating $89.7M in net income for fiscal year 2025 (8.9% net margin).
Dividend & Returns
Does ANIP pay dividends?
ANI Pharmaceuticals, Inc. (ANIP) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.
What is ANIP's return on equity?
ANI Pharmaceuticals, Inc. (ANIP) has a return on equity (ROE) of 16.2%. This is reasonable for most industries.
What is ANI Pharmaceuticals, Inc.'s free cash flow?
ANI Pharmaceuticals, Inc. (ANIP) generated $165.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.